Comparative Pharmacology
Head-to-head clinical analysis: REMERON versus REMERON SOLTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REMERON versus REMERON SOLTAB.
REMERON vs REMERON SOLTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mirtazapine is an antagonist at central presynaptic α2-adrenergic receptors, which increases central noradrenergic and serotonergic activity. It is also a potent antagonist of 5-HT2 and 5-HT3 receptors and H1 histamine receptors.
Mirtazapine is a tetracyclic antidepressant that acts as an antagonist at presynaptic α2-adrenergic autoreceptors and heteroreceptors, enhancing norepinephrine and serotonin release. It also antagonizes 5-HT2 and 5-HT3 receptors, and H1 and α1 receptors.
Initial: 15 mg orally once daily at bedtime, may increase every 1-2 weeks; usual effective dose: 15-45 mg/day; maximum: 45 mg/day.
15 to 45 mg orally once daily at bedtime, typically starting at 15 mg/day.
None Documented
None Documented
Terminal elimination half-life: 20-40 hours (mean 30 hours); longer in elderly (up to 60 hours) and patients with hepatic impairment
20-40 hours (mean 30 hours); prolonged in elderly (up to 60 hours) and hepatic impairment.
Renal: 75% (as metabolites, <1% unchanged); Fecal: 25% (as metabolites)
Renal: 75% (mostly as glucuronide conjugates, with 8-15% unchanged); Fecal: 15%; Biliary: minor.
Category C
Category C
Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)